Customer Demand Communication and Project Design
We begin by understanding your specific research objectives and collaboratively design a tailored experimental plan, outlining methodology and deliverables.
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
At Creative Biolabs, our extensive expertise in nucleic acid therapeutics empowers us to provide cutting-edge ribozyme-based anti-monkeypox drug discovery solutions. We help clients accelerate their antiviral research pipelines by delivering highly specific and potent therapeutic candidates against the monkeypox virus (MPXV).
The MPXV, an Orthopoxvirus, is a zoonotic pathogen that poses a significant public health threat. Human monkeypox disease presents with fever, body aches, swollen lymph nodes, and a characteristic rash. While existing vaccines offer some cross-protection and limited antivirals are available, current treatments often face limitations like side effects, accessibility, and resistance. This necessitates novel, highly specific, and potent therapeutic strategies to effectively combat MPXV.
Ribozymes, catalytic RNA molecules, offer a revolutionary approach. These "molecular scissors" precisely cleave specific RNA molecules, making them ideal for inactivating essential viral genetic material, like critical MPXV RNA sequences, within infected cells. Their inherent specificity and catalytic efficiency—where a single ribozyme can destroy multiple target RNA copies—provide a powerful tool to combat viral replication with minimal off-target effects, paving the way for next-generation antiviral interventions.
Fig.1 Mechanism of action of ribozyme.1
Creative Biolabs provides a comprehensive suite of services for the discovery and development of ribozyme-based anti-monkeypox drugs. Our integrated platform spans from initial target identification to advanced preclinical validation, ensuring a streamlined and efficient drug discovery process tailored to your specific research needs. We are dedicated to delivering innovative and effective solutions to address the urgent threat posed by MPXV.
We employ sophisticated bioinformatics and genomic analysis to pinpoint highly conserved and functionally critical RNA sequences within the MPXV genome, serving as optimal targets for ribozyme-mediated cleavage. This ensures maximum therapeutic impact.
Our expert team designs and optimizes ribozyme constructs, including hammerhead, hairpin, and HDV motifs, for superior catalytic efficiency, enhanced stability, and precise cellular delivery. We utilize computational modeling alongside empirical validation.
We perform rigorous in vitro cleavage assays to confirm the specific activity and potency of lead ribozyme candidates against their intended MPXV RNA targets. This includes gel-based assays and quantitative PCR to measure cleavage efficiency.
We conduct efficacy studies in appropriate animal models to assess the in vivo antiviral activity of ribozyme candidates, evaluating viral load reduction and disease progression.
Our team optimizes various delivery vehicles, such as lipid nanoparticles (LNPs) and viral vectors, to ensure efficient and targeted intracellular uptake of ribozymes in infected cells.
We analyze the absorption, distribution, metabolism, and excretion (ADME) profiles of ribozyme therapeutics, along with their pharmacodynamic effects, to inform dosing and formulation strategies.
We begin by understanding your specific research objectives and collaboratively design a tailored experimental plan, outlining methodology and deliverables.
Upon mutual agreement, we formalize our partnership with a clear contract, detailing terms and timelines, and promptly initiate preparatory phases.
This involves rigorous in vitro and in vivo studies. Our scientists, using state-of-the-art facilities and strict protocols, perform core operations like ribozyme synthesis, target validation, and preclinical evaluations, ensuring precise, reliable data.
Subsequently, our experts transform raw data into professional, insightful reports with clear interpretations for informed decision-making.
We provide all finalized data, comprehensive reports, and lead candidates. We also offer dedicated follow-up consultation and strategic guidance to confidently advance your discovery efforts.
Click the button to contact us for service details and a custom quote.
Ribozymes exert their antiviral effect by precisely targeting and cleaving specific RNA molecules essential for the MPXV life cycle. Upon entering an infected cell, an engineered ribozyme recognizes a complementary sequence on a critical viral RNA, such as the mRNA encoding the viral DNA polymerase, which is indispensable for replication. Another key target is the MPXV pregenomic RNA, vital for viral propagation. Through Watson-Crick base pairing, the ribozyme binds to its target and then catalytically cleaves the phosphodiester backbone of the RNA. This irreversible cleavage renders the viral RNA non-functional, thereby preventing the synthesis of crucial viral proteins or disrupting essential replication processes, effectively halting the viral infection at its source.
Precision Targeting
Our ribozyme designs ensure unparalleled specificity, minimizing off-target effects and enhancing the safety profile of potential therapeutics.
Catalytic Efficiency
Leveraging the catalytic nature of ribozymes, our solutions offer high potency, enabling effective viral suppression at lower concentrations.
Rapid Adaptability
The modular design of ribozymes allows for swift modification and optimization against emerging MPXV strains or evolving resistance mechanisms.
Integrated Platform
We provide a seamless, end-to-end service, from initial target identification and ribozyme design to robust in vitro and in vivo validation.
Ribozyme-based therapies offer a distinct advantage through their highly specific, sequence-dependent RNA cleavage mechanism. Unlike many traditional small molecules that broadly inhibit viral enzymes, ribozymes precisely target and destroy essential viral RNA, leading to fewer off-target effects and a potentially safer therapeutic profile. Their catalytic nature also means a single ribozyme molecule can inactivate multiple viral RNA targets, enhancing potency.
Our specificity assurance begins with advanced bioinformatics analysis of the MPXV genome to identify unique, highly conserved viral RNA sequences that are critical for viral replication but absent in host cells. We then employ rational design principles and computational modeling to engineer ribozymes with perfect complementarity to these targets, followed by rigorous in vitro validation using molecular assays to confirm precise cleavage and minimal off-target activity.
We leverage a range of well-characterized and highly efficient ribozyme motifs to suit diverse therapeutic needs. Our expertise includes the versatile hammerhead ribozymes, known for their compact structure and robust activity, the more complex but equally potent hairpin ribozymes, and the highly catalytic Hepatitis Delta Virus (HDV) ribozymes, all of which can be engineered for optimal performance against specific MPXV targets.
Absolutely. One of the significant strengths of ribozyme technology is its inherent adaptability. Given the known genomic sequence of any new MPXV variant, our platform allows for rapid redesign and optimization of ribozymes to target conserved or novel essential RNA sequences within the mutated viral genome, enabling a quick response to emerging threats.
Delivering nucleic acid therapeutics like ribozymes efficiently into target cells can be challenging due to their size and susceptibility to degradation. We address this by actively developing and optimizing various advanced delivery vehicles, including LNPs and viral vectors, which are designed to protect the ribozymes and facilitate their targeted and efficient intracellular uptake.
At Creative Biolabs, we provide ribozyme-based monkeypox drug development services to our clients all over the world. If you are interested in our monkeypox research products and anti-monkeypox drug discovery solutions, please feel free to contact us for more information.
Reference
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.